Abstract:Background: Corneal neovascularization (NV) is a process of abnormal vessel growth into the transparent cornea from the limbus and can disturb the light passing through the cornea, resulting in vision loss or even blindness. The use of nanomedicine as an effective therapeutic formulation in ophthalmology has led to higher drug bioavailability and a slow drug release rate. In this research, we designed and explored the feasibility of a new nanomedicine, gp91 ds-tat (gp91) peptide-encapsulated gelatin nanoparticles (GNP-gp91), for inhibiting corneal angiogenesis. Methods: GNP-gp91 were prepared by a two-step desolvation method. The characterization and cytocompatibility of GNP-gp91 were analyzed. The inhibition effect of GNP-gp91 on HUVEC cell migration and tube formation was observed by an inverted microscope. The drug retention test in mouse cornea was observed by in vivo imaging system, fluorescence microscope, and DAPI/TAMRA staining. Finally, the therapeutic efficacy and evaluation of neovascularization-related factors were conducted through the in vivo corneal NV mice model via topical delivery. Results: The prepared GNP-gp91 had a nano-scale diameter (550.6 nm) with positive charge (21.7 mV) slow-release behavior (25%, 240hr). In vitro test revealed that GNP-gp91 enhanced the inhibition of cell migration and tube formation capacity via higher internalization of HUVEC. Topical administration (eyedrops) of the GNP-gp91 significantly prolongs the retention time (46%, 20 min) in the mouse cornea. In chemically burned corneal neovascularization models, corneal vessel area with a significant reduction in GNP-gp91 group (7.89%) was revealed when compared with PBS (33.99%) and gp91 (19.67%) treated groups via every two days dosing. Moreover, GNP-gp91 significantly reduced the concentration of Nox2, VEGF and MMP9 in NV's cornea. Conclusion: The nanomedicine, GNP-gp91, was successfully synthesized for ophthalmological application. These data suggest that GNP-gp91 contained eyedrops that not only have a longer retention time on the cornea but also can treat mice corneal NV effectively delivered in a low dosing frequency, GNP-gp91 eyedrops provides an alternative strategy for clinical ocular disease treatment in the culture.

Dasatinib Loaded Nanostructured Lipid Carriers for Effective Treatment of Corneal Neovascularization

Dasatinib and erianin co-loaded ion-responsive in-situ hydrogel for effective treatment of corneal neovascularization

A Synergistic Therapy with Antioxidant and Anti-VEGF: Toward Its Safe and Effective Elimination for Corneal Neovascularization

An Active Transport Dual Adaptive Nanocarrier Designed to Overcome the Corneal Microenvironment for Neovascularization Therapy.

A Synergistic Therapy with Antioxidant and Anti‐VEGF: Towards Its Safe and Effective Elimination for Corneal Neovascularization

Biomimetic Nanocomplex Based Corneal Neovascularization Theranostics.

A SU6668 pure nanoparticle-based eyedrops: toward its high drug Accumulation and Long-time treatment for corneal neovascularization

Targeted Dexamethasone Nano-Prodrug for Corneal Neovascularization Management.

A Novel, Liposome-Loaded, Injectable Hydrogel for Enhanced Treatment of Choroidal Neovascularization by Sub-Tenon's Injection

Development of injectable hyaluronic acid-based hydrogels with antioxidant activity for the treatment of corneal neovascularization

Sunitinib malate-loaded biodegradable microspheres for the prevention of corneal neovascularization in rats

Development of mucoadhesive cationic polypeptide micelles for sustained cabozantinib release and inhibition of corneal neovascularization.

Targeted Long-term Noninvasive Treatment of Choroidal Neovascularization by Biodegradable Nanoparticles

Micellar delivery of dasatinib for the inhibition of pathologic cellular processes of the retinal pigment epithelium.

Dexamethasone-loaded ROS stimuli-responsive nanogels for topical ocular therapy of corneal neovascularization

Liposomal sunitinib for ocular drug delivery: A potential treatment for choroidal neovascularization

Innovative platelet-derived extracellular vesicle drug delivery system for the treatment of corneal neovascularization

Topical ocular delivery to laser-induced choroidal neovascularization by dual internalizing RGD and TAT peptide-modified nanoparticles

Functional Peptide-Loaded Gelatin Nanoparticles as Eyedrops for Cornea Neovascularization Treatment

Nanoparticle-mediated corneal neovascularization treatments: Toward new generation of drug delivery systems

Antiangiogenic Nanomicelles for the Topical Delivery of Aflibercept to Treat Retinal Neovascular Disease